Download PDF
Pharmacopsychiatry 2003; 36: 168-175
DOI: 10.1055/s-2003-45126
Original Paper
© Georg Thieme Verlag Stuttgart · New York

Modern Treatment Concepts in Schizophrenia

W. Gaebel1 , B. Janssen1 , M. Riesbeck1
  • 1Department of Psychiatry, Heinrich-Heine-University - Rhineland State Clinics Düsseldorf, Düsseldorf, Germany
Further Information

Publication History

Publication Date:
15 December 2003 (online)

Also available at
    Permissions and Reprints

On the basis of available practice guidelines for schizophrenia, contemporary treatment principles for schizophrenia leading to phase- or stage-oriented, multidimensional treatment approaches are described. Additionally, based on current research programmes, future treatment developments are presented.

References

  • 1 American Psychiatric A ssociation. Practice guidelines for the treatment of patients with schizophrenia.  Am J Psychiatry. 1997;  154 4 (suppl)
    PubMedGoogle Scholar
  • 2 American Psychiatric A ssociation. Quick reference to the American Psychiatric Association Practice Guidelines for the treatment of psychiatric disorders: compendium 2002. American Psychiatric Publishing Arlington; 2002
    Google Scholar
  • 3 Amminger G P, Edwards J, Brewer W J, Harrigan S, McGorry P D. Duration of untreated psychosis and cognitive deterioration in first-episode schizophrenia.  Schizophr Res. 2002;  54 223-230
    CrossrefPubMedGoogle Scholar
  • 4 Basile V S, Masellis M, Potkin S G, Kennedy J L. Pharmacogenomics in schizophrenia: the quest for individualized therapy.  Hum Mol Genet. 2002;  11 2517-2530
    CrossrefPubMedGoogle Scholar
  • 5 Bechdolf A, Wagner M, Kühn K -U, Streit M, Bottlender R, Wieneke A, Schultze-Lutter F, Maier W, Klosterkötter J, Ruhrmann S. Interventions in the initial prodromal states of psychosis in Germany: concept and first results. Br J Psychiatry 2003 (submitted)
    Google Scholar
  • 6 Bleuler M. Die schizophrenen Geistesstörungen im Lichte langjähriger Kranken- und Familiengeschichten. Stuttgart/New York; Thieme 1972
    Google Scholar
  • 7 Breier A, Schreiber J L, Dyer J, Pickar D. Course of illness and predictors of outcome in chronic schizophrenia: Implications for pathophysiology.  Br J Psychiatry. 1992;  161 (suppl 18) 38-43
    PubMedGoogle Scholar
  • 8 Csernansky J G, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.  N Engl J Med. 2002;  346 16-22
    CrossrefPubMedGoogle Scholar
  • 9 Emsley R. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study.  Schizophr Bull. 1999;  25 (4) 721-729
    PubMedGoogle Scholar
  • 10 Frommann N, Streit M, Wölwer W. Remediation of facial affect recognition impairments in patients with schizophrenia: a new training program.  Psychiatry Res. 2003;  117 281-284
    CrossrefPubMedGoogle Scholar
  • 11 Gaebel W. Leitlinien störungspezifischer Diagnostik und Therapie - Schizophrenie. In: Gaebel W, Müller-Spahn F (eds) Diagnostik und Therapie psychischer Störungen. Stuttgart/Berlin; Kohlhammer 2002
    Google Scholar
  • 12 Gaebel W, Jänner M, Frommann N, Pietzcker A, Kopcke W, Linden M, Müller P, Müller-Spahn F, Tegeler J. Prodromal states in schizophrenia.  Compr Psychiatry. 2000;  41 76-85
    PubMedGoogle Scholar
  • 13 Gaebel W, Jänner M, Frommann N, Pietzcker A, Köpcke W, Linden M, Müller P, Müller-Spahn F, Tegeler J. First vs. multiple episode schizophrenia: Two-year outcome of intermittent and maintenance medication strategies.  Schizophr Res. 2002;  53 145-159
    Google Scholar
  • 14 Gaebel W, Riesbeck M. Differentielle Indikation zur pharmakologischen Langzeittherapie bei Patienten mit schizophrenen Störungen. In: Fleischhacker WW, Hummer M (eds) Schizophrene Störungen - State of the Art. Innsbruck; VIP-Verlag Integrative Psychiatrie 2003 (in press)
    Google Scholar
  • 15 Geddes J. Prevention of relapse in schizophrenia.  N Engl J Med. 2002;  346 56-58
    PubMedGoogle Scholar
  • 16 Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systemic overview and meta-regression analysis.  BMJ. 2000;  32 1371-1376
    PubMedGoogle Scholar
  • 17 Goodman A. Organic unity theory: the mind-body problem revisited.  Am J Psychiatry. 1991;  148 553-563
    PubMedGoogle Scholar
  • 18 Gould R A, Mueser K T, Bolton E, Mays V, Goff D. Cognitive therapy for psychosis in schizophrenia: an effect size analysis.  Schizophr Res. 2001;  48 335-342
    CrossrefPubMedGoogle Scholar
  • 19 Green M F, Marder R S, Glynn S M, McGurk S R, Wirshing W C, Wirshing D A, Liberman R P, Mintz J. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone.  Biol Psychiatry. 2002;  51 972-978
    CrossrefPubMedGoogle Scholar
  • 20 Grimshaw J M, Russell I T. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations.  Lancet. 1993;  342 1317-1322
    CrossrefPubMedGoogle Scholar
  • 21 Herz M I, Lamberti S J. Prodromal symptoms and relapse prevention in schizophrenia.  Schizophr Bull. 1995;  21 (4) 541-551
    PubMedGoogle Scholar
  • 22 Janssen B, Pourhassan F, Menke R, Vauth R, Schneider F, Gaebel W. Quality improvement in outpatient care of schizophrenic patients: a multicenter study.  Schizophr Res. 2001;  49 272
    PubMedGoogle Scholar
  • 23 Kahn R S, Fleischhacker W, Keet R. et al . The European First Episode Schizophrenia Trial (EUFEST). Comparison of outcome in first episode schizophrenia with different antipsychotic drug regimes. 2001 (unpublished manuscript)
    Google Scholar
  • 24 Koch K, Habel U, Frommann N, Klein M, Shah N J, Kellermann T, Brinkmeyer J, Streit M, Zilles K, Wölwer W, Schneider F. Emotion discrimination training modifies functional cerebral correlates in schizophrenia patients.  Neuroimage. 2003;  18 (suppl) (in press)
    PubMedGoogle Scholar
  • 25 Larsen T K, Friis S, Haahr U, Joa I, Johannessen J O, Melle I, Opjordsmoen S, Simonsen E, Vaglum P. Early detection and intervention in first-episode schizophrenia: a critical review.  Acta Psychiatrica Scandinavica. 2001;  103 323-334
    CrossrefPubMedGoogle Scholar
  • 26 Lehman A F. Evaluating outcomes of treatments for persons with psychotic disorders.  J Clin Psychiatry. 1996;  57 (suppl 11) 61-67
    PubMedGoogle Scholar
  • 27 Lehman A F, Steinwachs DM and the Co-Investigators of the P ORT-Project. At issue: translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations.  Schizophr Bull. 1998;  24 1-10
    PubMedGoogle Scholar
  • 28 Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.  Schizophr Res. 1999;  35 51-68
    CrossrefPubMedGoogle Scholar
  • 29 Leucht S, Pitschel-Walz G, Engel R R, Kissling W. Amisulpride, an unusual ”atypical” antipsychotic: a meta-analysis of randomized controlled trials.  Am J Psychiatry. 2002;  159 (2) 180-190
    CrossrefPubMedGoogle Scholar
  • 30 Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis.  Lancet. 2003;  361 1581-1589
    CrossrefPubMedGoogle Scholar
  • 31 Levinson D F, Umapathy C, Musthaq M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms.  Am J Psychiatry. 1999;  156 1138-1148
    PubMedGoogle Scholar
  • 32 Lewis S, Tarrier N, Haddock G, Bentall R, Kinderman P, Kingdon D, Siddle R, Drake R, Everitt J, Leadley K, Benn A, Grazebrook K, Haley C, Akhtar S, Davies L, Palmer S, Faragher B, Dunn G. Randomised controlled trial of cognitive-behavioural therapy in early schizophrenia: acute-phase outcomes.  Br J Psychiatry. 2002;  43 (suppl) 91-97
    Google Scholar
  • 33 Lieberman J. Comparative effectiveness of antipsychotic medications in patients with schizophrenia (trial design summary). 2000
    Google Scholar
  • 34 Linszen D, Dingemans P, Lenior M. Early intervention and a five year follow up in young adults with a short duration of untreated psychosis: ethical implications.  Schizophr Res. 2001;  51 55-61
    CrossrefPubMedGoogle Scholar
  • 35 Marder S. Antipsychotic drugs and relapse prevention.  Schizophr Res. 1999;  35 S87-92
    CrossrefPubMedGoogle Scholar
  • 36 Marder R S, Essock S M, Miller A L, Buchanan R W, Davis J M, Kane J M, Lieberman J, Schooler N R. The Mount Sinai Conference on the Pharmacotherapy of Schizophrenia.  Schizophr Bull. 2002;  28 5-16
    CrossrefPubMedGoogle Scholar
  • 37 May P RA, Tuma A H, Yale C, Potepan P, Dixon W J. Schizophrenia - A follow-up study of results of treatment. II. Hospital stay over two to five years.  Arch Gen Psychiatry. 1976;  33 481-486
    PubMedGoogle Scholar
  • 38 McEvoy J, Scheifler P, Frances A. The expert consensus guideline series: Treatment of schizophrenia 1999.  J Clin Psychiatry. 1999;  60 (suppl 11) 3-80
    PubMedGoogle Scholar
  • 39 McGorry P D, Yung A, Phillips L. Ethics and early intervention in psychosis: keeping up the pace and staying in step.  Schizophr Res. 2001;  51 17-29
    CrossrefPubMedGoogle Scholar
  • 40 McGorry P D, Yung A R, Phillips L J, Yuen H P, Francey S, Cosgrave E M, Germano D, Bravin J, McDonald T, Blair A, Adlard S, Jackson H. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms.  Arch Gen Psychiatry. 2002;  59 921-928
    Google Scholar
  • 41 Mrazek PJ & Haggarty R J. Committee on prevention of mental disorders. Washington DC; National Academy Press 1994
    Google Scholar
  • 42 National Institute for Clinical Excellence ( NICE). Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal Guidance 2002: 43 (www.nice.org.uk)
    Google Scholar
  • 43 Nuechterlein K H, Dawson M E. A heuristic vulnerability/stress model of schizophrenic episodes.  Schizophr Bull. 1984;  10 300-312
    PubMedGoogle Scholar
  • 44 Rector N A, Beck A T. Cognitive behavioral therapy for schizophrenia: an empirical review.  J Nerv Ment Dis. 2001;  189 278-287
    Google Scholar
  • 45 Rietschel M, Kennedy J L, Macciardi F, Meltzer H Y. Application of pharmacogenetics to psychotic disorders: the first consensus conference. The Consensus Group for Outcome Measures in Psychoses for Pharmacological Studies.  Schizophr Res. 1999;  37 191-196
    CrossrefPubMedGoogle Scholar
  • 46 Sanger T M, Lieberman J A, Tohen M, Grundy S, Beasley C, Tollefson G. Olanzapine versus haloperidol treatment in first-episode psychosis.  Am J Psychiatry. 1999;  156 79-87
    PubMedGoogle Scholar
  • 47 Sartorius N, Fleischhacker W, Gjerris A, Kern U, Knapp M, Leonard B, Lieberman J, López-Ibor J, Van Raay B, Twomey E. The usefulness and use of second-generation antipsychotic medications.  Current Opinion in Psychiatry. 2002;  15 (suppl) 1-51
    CrossrefPubMedGoogle Scholar
  • 48 Scatton B, Sanger D J. Pharmacological and molecular targets in the search for novel antipsychotics.  Behavioural Pharmacology. 2000;  11 243-256
    PubMedGoogle Scholar
  • 49 Streit M, Wölwer W, Gaebel W. Facial-affect recognition and visual scanning behaviour in the course of schizophrenia.  Schizophr Res. 1997;  24 311-317
    CrossrefPubMedGoogle Scholar
  • 50 van Os J, Hanssen M, Bijl R V, Vollebergh W. Prevalence of psychotic disorder and community level of psychotic symptoms. An urban-rural comparison.  Arch Gen Psychiatry. 2001;  58 663-668
    PubMedGoogle Scholar
  • 51 Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life.  Schizophr Res. 2000;  43 135-145
    CrossrefPubMedGoogle Scholar
  • 52 Wagner M, Frommann I, Brinkmeyer J, Wölwer W, Schröter A, Matuschek E, Pukrop R. Neuropsychological deficits in presumably prodromal subjects.  European Archives of Psychiatry and Clinical Neuroscience. 2002;  252 2-3
    PubMedGoogle Scholar

Prof. Dr. Wolfgang Gaebel

Department of Psychiatry

Heinrich-Heine-University

Rhineland State Clinics Düsseldorf

Bergische Landstraße 2

40629 Düsseldorf - Germany

Phone: 049 211-922-2000

Fax: 049 211-922-2020

Email: wolfgang.gaebel@uni-duesseldorf.de

      >